Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-Blind Placebo-controlled, Parallel-group Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia

NCT03092726 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.

NCT NCT03092726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03092726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-Blind Placebo-controlled, Parallel-group Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia
Lead sponsor
Astellas Pharma Global Development, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 8, 2017
Completion date
March 6, 2018
Enrollment
183 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

fibromyalgia